science π¬ BCLXL rewires cancer response to PARP inhibitors
BCLXL has been implicated in both apoptosis resistance and prolonging senescent cell survival in various cancers. This anti-apoptotic protein is frequently overexpressed in cancers like ovarian cancer due to gene amplification. The study examined PARPi-resistant ovarian cancer models to understand cell death mechanisms. Researchers found that BCLXL neutralizes pro-apoptotic signals activated by PARPi treatment. Adding the selective BCLXL inhibitor A-1155463 partially restored sensitivity to PARPi in vitro and in vivo. π¬